We study statistical methods to detect cancer genes that are over-or downexpressed in some but not all samples in a disease group. This has proven useful in cancer studies where oncogenes are activated only in a small subset of samples. We propose the outlier robust t-statistic, which is intuitively motivated from the t-statistic, the most commonly used differential gene expression detection method. Using real and simulation studies, we compare the outlier robust t-statistic to the recently proposed COPA of Tomlins et al. (2005) and the outlier sum statistic of Tibshirani and Hastie (2006) . The proposed method often has more detection power and smaller false discovery rates. Supplementary information can be found at
Introduction
Recently Tomlins et al. (2005) have proposed the "cancer outlier profile analysis" (COPA) method for detecting cancer genes which show increased expressions in a subset of disease samples. They argue that in the majority of cancer types, oncogene has heterogeneous activation patterns; traditional analytical methods, e.g., t-statistic, which search for common activation of genes across a class of cancer samples, will fail to find such oncogene expression profiles. Instead, we should search for over-expression only in a subset of cases. Through applications to public cancer microarray data sets, they have shown that the proposed COPA can perform better than the commonly used t-statistic.
More recently Tibshirani and Hastie (2006) proposed the outlier sum (OS) statistic to detect cancer gene outlier expressions. The OS and COPA are similarly defined using robust location and scale estimates of the gene expression values (more details in Section 2). Through simulation studies and applications, they have shown that the OS can perform better than the COPA, e.g., having smaller false discovery rates (Benjamini and Hochberg, 1995) .
In this paper, we consider the statistical methods to detect cancer genes with a subset of over-or down-expressed outlier disease samples. Many methods have been proposed to detect differentially expressed genes (see Dudoit et al., 2002; Troyanskaya et al., 2002, e.g.) . Among them, the t-statistic is the most commonly used method. We will discuss several problems associated with the t-statistic for cancer gene outlier expression detection, which will motivate the development of the outlier robust t-statistic (ORT). We will further establish the connection of the OS, COPA and ORT statistics to the t-statistic from a robustness consideration. Through simulation studies and applications to a public breast cancer microarray data, we empirically evaluate and compare the different outlier detection statistics.
Statistical methods
Consider a two-class, e.g., cancer/normal tissues, microarray data. Let x ij be the observed expression values for samples i = 1, · · · , n and genes j = 1, · · · , p. Without loss of generality, assume the first n 1 samples are from the normal group and the last n 2 samples are from the cancer group, where n = n 1 + n 2 . In the following discussion, we assume the outlier disease samples are over-expressed. Similar arguments will carry through to detect genes with down-expressed outlier disease samples.
The two sample t-test statistic for gene j is defined as
Here s j is the pooled standard error estimate for gene j
The t-statistic is based on the assumption that all disease samples are over expressed. While in cancer gene outlier analysis, only a subset of the disease samples are assumed to be over expressed. Intuitively we want to make inference only using those over-expressed samples (outliers).
In the following we first study the recently proposed "cancer outlier profile analysis" method (COPA; Tomlins et al., 2005) and the outlier sum statistic (OS; Tibshirani and Hastie, 2006) for detecting cancer gene outliers. We will make some intuitive connections between these two outlier detection statistics and the t-statistic. The t-statistic (1) will be studied from a robustness (against outlier) perspective, which shows its dependence on all disease samples and the inappropriate variance estimate. We then propose an outlier robust t-statistic (ORT) to remove the "all disease samples" dependence and appropriately reduce the outlier effects on the variance.
T-statistic, COPA and OS
Notice that we can equivalently write the t-statistic (1) as
where avg(·) means the sample average; avg 1j and avg 2j are the normal and disease group sample means. According to our assumption, only a subset of those disease samples (i>n 1 ) are over-expressed. So the avg i>n 1 (·) in the nominator, which sums over all disease samples, will introduce some extra noise. Another problem is the variance estimate, which might over-estimate the true value since we already know there are a subset of outlier disease samples. The COPA and OS statistics address these two problems with their different approaches. They are defined as follows. First (robustly) standardize the datã
where med j is the median and mad j is the median absolute deviation of gene j's expression values
where the constant 1.4826 makes mad j approximately equal to the standard error for normally distributed random variables. Here the medians are used due to the robustness consideration. Let q r (·) be the r th percentile of the data. The COPA statistic (Tomlins et al., 2005 ) is defined as the r th percentile of the disease samples' standardized expression values: q r (x ij : i > n 1 ), where the authors have used r = 75, 90, or 95. Notice that the subtraction and scaling would not change the order of the observed values. So it is easily checked that the COPA statistic is equivalent to
Compared to the t-statistic, intuitively the COPA replaces the normal sample meanx 1j by the all sample median med j ; the sample standard error s j by the median absolute deviation mad j ; and the disease sample meanx 2j by the r th percentile q r (x ij : i > n 1 ).
Here mad j can be viewed as a scaling factor to make the COPA statistics comparable across different genes.
Immediately we can see that the COPA statistic might not be efficient, since a fixed r th sample percentile is approximately equivalent to using the information from only one sample. We expect to see improved power if instead we sum over, ideally, all outlier disease samples. The OS statistic (Tibshirani and Hastie, 2006) proposed to replace the r th percentile with a sum over the outlier disease samples identified with some heuristic criterion. The OS statistic is defined as
where I(·) is the indicator function and IQR(·) calculates the interquartile range
It is commented that values greater than the limit q 75 + IQR are defined to be outliers in the usual statistical sense.
Similarly since the subtraction and scaling would not change the order of the observed values. It is easily checked that the OS statistic is equivalent to
where R is the set of "outlier disease samples" defined by the following heuristic criterion
Outlier robust t-statistic (ORT)
Besides the inefficiency of the COPA statistic owing to its use of a fixed r th sample percentile, a second problem is that the median over all samples, med j , is not quite the right statistic to replace the normal sample mean, avg 1j . It might over-estimate the normal group mean owing to the contamination by disease samples if a majority of them have outlier expressions. A more intuitive and appropriate quantity might be, e.g., the normal sample median.
Another problem is the median absolute deviation estimation. Since we already know that the disease and normal samples are different, it might not be the best approach to use the overall median as a common estimate for the two group medians. Intuitively it might help to base our estimate on, e.g., the group median centered expression values
where med 1j and med 2j are the sample medians for the normal and disease groups med 1j = median i≤n 1 (x ij ), med 2j = median i>n 1 (x ij ) An intuitive and reasonable estimate for the median absolute deviation might then be, e.g.
which is in spirit very similar to the pooled sample variance estimate
In essence, we use the sample median to replace average, and the absolute difference to replace squared difference in order to obtain a more robust variance estimate. Summarizing previous discussions, we propose the following outlier robust t-statistic (ORT) to detect cancer genes with over-expressed outlier disease samples
where U j is the set of "outlier disease samples" for gene j defined by
Notice that here we explicitly calculate the outlying measures using only the normal group samples. We use permutations to estimate the ORT's null distribution and calculate the p-values. For simplicity we omit those constants in the statistic definition, since they would not affect the significance testing based on the permutations.
In the following, we use simulation studies and applications to a public breast cancer microarray data to empirically evaluate and compare the detection power of previously discussed four methods: the t-statistic, COPA, OS, and the proposed ORT.
Simulation studies
Simulation studies are conducted to evaluate the power of various outlier detection statistics. We also compare their false discovery rates (Benjamini and Hochberg, 1995) .
Suppose we have n = 25 normal and disease samples. There are total p = 1000 genes with their expression values simulated from the standard normal distribution. The first gene contains k = 1, 5, 10, 15, 20, 25 outlier disease samples with their expression values being added constant µ = 2. For each simulated data, we can calculate the p-value for the first gene, which is the proportion of the other (null) genes with the absolute test statistics bigger than the first gene. The p-values from the simulations can be used to estimate the true/false positive rates, i.e., the sensitivity and 1-specificity, which are then used to construct the ROC curve for power comparison. Figure 1 shows the estimated true/false positive rates based on 1000 simulations. In the extreme situation with only one outlier disease sample (k = 1), the OS statistic performs the best; the ORT has comparable performance as the OS; the t-statistic and COPA have almost no detection power. When increasing to k = 5 outlier disease samples, the ORT, OS and COPA have similar power, all better than the t-statistic. For k = 10 outlier disease samples, ORT performs the best. The detection power of both the ORT and t-statistic increases with more outlier disease samples. While the performance of the COPA and OS decreases a little bit when the outlier disease samples approach the full set (k = 20, 25). Overall, the ORT performs the best. It seems to be able to automatically adapt to the unknown number of outlier samples, and combine the strength of both the OS and t-statistic. Next we evaluate and compare the false discovery rates of the four methods based on the simulation. We set m = 100, 200, 300 of the p = 1000 genes as differentially expressed with k = 1, 5, 15, 20, 25 outlier disease samples with their expression values being added constant µ = 2. Figure 2 shows the estimated false discovery rates based on 1000 simulations for m = 200 differentially expressed genes. Similar patterns as the true/false positive rates estimation (see Figure 1 ) are observed. The ORT has the overall best performance with the smallest false discovery rates. Very similar patterns have been observed for m = 100, 300. We also did the simulation studies for n = 15, 25; k = 1, 3, 6, 9, 12, 15 or k = 1, 5, 10, 15, 20, 25; and µ = 1, 2. We consistently observe that the ORT has the overall best performance. Complete simulation results are available at the supplementary website.
In the next section, we apply the four cancer gene outlier detection statistics to a public breast cancer microarray data and empirically compare their performance.
Application to the breast cancer microarray data
The breast cancer microarray data reported by West et al. (2001) contained the expression levels of 7129 genes from 49 breast tumor samples. Each sample had a binary outcome describing the status of lymph node involvement in breast cancer. Among them, 25 tumor samples had no positive lymph nodes discovered and 24 tumor samples had identifiably positive nodes. The gene expressions, obtained from the Affymetrix human HuGeneFL GeneChip, can be downloaded from http://data.cgt.duke.edu/west.php. We normalize the data using quantile normalization (Bolstad et al., 2003) , and then log transform the intensities for followup statistical analysis. In the cancer gene outlier detection, we treat the negative group as the normal class. We applied the t-statistic, COPA, OS, and the proposed ORT to detect genes with over-expressed disease samples. We rank the genes based on each test statistic. For those top 25 genes identified by each method, we mapped their Affymetrix identifiers to the UniGene cluster identifiers using the Bioconductor (Gentleman et al., 2004) annotation package hu6800, which were then used to search for relevant literature in the PubMed. There are total 13 genes identified that have been studied previously and shown related to breast cancer. Table 1 lists the confirmed breast cancer related genes ranked in top 25 for each outlier detection statistic. ORT identified 8 genes, 5 of them were not selected by other statistics. There were 5 genes that were missed by the ORT but identified by the others. Also listed in the table is the ranking of each gene by the four test statistics. The genes identified by the OS were ranked generally high by the ORT. Among those genes identified by the ORT, some were ranked low by the OS but relatively higher by the t-statistic, e.g., ATM and ERBB4; while several others were ranked low by the t-statistic but relatively higher by the OS, e.g., AGTR1 and CASC3. It seems like the proposed ORT could combine the strength of both the OS and t-statistic (see also Figures 1 and 2 in the simulation study section). Overall the ORT had the best detection power. Figure 3 shows the expression profiles of the 8 genes that were identified by the ORT and confirmed associated with the breast cancer in previous studies. Figure 4 shows the expression profiles of the other 5 confirmed breast cancer related genes that were missed by the ORT but identified by the other three methods. We have added some jittering to the horizontal positions to distinguish among close points. The title lists the gene names. Within the parentheses are those outlier statistics that have ranked the gene in top 25.
Discussion
Previous discussions have focused on detecting genes with over-expressed outlier disease samples. The proposed ORT can be adapted to detect cancer genes with down-expressed outlier disease samples as follows 
